0.627
-0.01 (-1.72%)
| Penutupan Terdahulu | 0.638 |
| Jumlah Dagangan | 30,529 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -0.110 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.69% |
| Nisbah Semasa (MRQ) | 1.02 |
| Aliran Tunai Operasi (OCF TTM) | -1.53 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -8.99 M |
| Pulangan Atas Aset (ROA TTM) | -84.13% |
| Pulangan Atas Ekuiti (ROE TTM) | -250.49% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Tiziana Life Sciences Ltd | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -2.1 |
| Persekitaran Makro | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | -0.34 |
|
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 43.06% |
| % Dimiliki oleh Institusi | 2.73% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Mid-American Wealth Advisory Group, Inc. | 30 Sep 2026 | 448,667 |
| Venture Visionary Partners Llc | 30 Sep 2026 | 20,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |